Two major studies casting doubt on the ability of antimalaria drugs to treat Covid-19 patients based on data from a little-known Chicago company, Surgisphere Corp., were retracted Thursday.
The Lancet first pulled a study published late last month that found antimalarials provided no benefit as a treatment for Covid-19 infections while increasing the risk of heart problems and death. The New England Journal of Medicine then retracted a separate article, published in early May, that examined the impact of cardiovascular and…
READ THE FULL ARTICLE AT THE WALL STREET JOURNAL HERE